Palatin Technologies : Phase 2 Clinical Study Of PL8177 In Patients With Ulcerative Colitis Currently Expected To Start Next Quarter With Top-Line Results Expected In The Second Half Calendar 2022 (Form 8-K) : Comparemela.com

vimarsana.com

Palatin Technologies : Phase 2 Clinical Study of PL8177 in Patients with Ulcerative Colitis Currently Expected to Start Next Quarter with Top-Line Results Expected in the Second Half Calendar 2022 (Form 8-K)

Card image cap

Palatin Technologies : Phase 2 Clinical Study of PL8177 in Patients with Ulcerative Colitis Currently Expected to Start Next Quarter with Top-Line Results Expected in the Second Half Calendar 2022 (Form 8-K)

marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

Related Keywords

United States , America , American , Michaelb Raizman , Paul Arndt , Carl Spana , Jamese Hattersley , J Don Wang , Prnewswire Palatin Technologies Inc , Drug Administration , Exchange Commission , American Society Of Cataract , Palatin Technologies Inc , Product Development , Securities Exchange , Association For Research , Business Development , Ulcerative Colitis Currently Expected , Start Next Quarter , Top Line Results Expected , Second Half Calendar , Cash Equivalents , Cash Runway Through Calendar , Upcoming Events , Autoimmune Programs , New Drug Application , American Society , Refractive Surgery Annual , Key Opinion Leader , Retina Specialists , Leadership Additions , Chief Medical Officer , Senior Vice President , Vice President , Hypoactive Sexual Desire Disorder , Fiscal Year Ended , North America , Melanocortin Receptor Agonists , Palatin Technologies , Securities Act , Securities Exchange Act , Private Securities Litigation Reform Act , Investor Inquiries , Media Inquiries , Lifesci Advisors , Financial Statement Data Follows , Months Ended June , Ended June ,

comparemela.com © 2020. All Rights Reserved.